{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:16:20Z","timestamp":1790381780474,"version":"4.1.0"},"reference-count":175,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R01 AI135005"],"award-info":[{"award-number":["R01 AI135005"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["U19AI166761"],"award-info":[{"award-number":["U19AI166761"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["F31AI186506"],"award-info":[{"award-number":["F31AI186506"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Coccidioides immitis and C. posadasii are the causative agents of coccidioidomycosis (CM) or Valley Fever, endemic to the alkaline deserts of North and South America. Clinical treatment of CM is predominantly limited to the triazole and polyene drug classes. There are limited therapeutic options for the treatment of CM, most commonly requiring prolonged courses of therapy with established antifungal agents such as azoles and Amphotericin B, which often lead to toxicity and drug resistance. Clearly, there is a need to develop novel and better antifungal drugs against CM. This review examines both repurposed and recently discovered compounds in various stages of development for the treatment of CM.<\/jats:p>","DOI":"10.3390\/jof11120875","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:11:18Z","timestamp":1765383078000},"page":"875","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Drug Discovery and Repurposing for Coccidioides: A Systematic Review"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4959-3321","authenticated-orcid":false,"given":"Sarah","family":"Saeger","sequence":"first","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4593-159X","authenticated-orcid":false,"given":"Sofia","family":"Lozano","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-5122","authenticated-orcid":false,"given":"Nathan","family":"Wiederhold","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas at San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8901-3366","authenticated-orcid":false,"given":"Jieh-Juen","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1992-3270","authenticated-orcid":false,"given":"Jose L.","family":"Lopez-Ribot","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1091-3420","authenticated-orcid":false,"given":"Chiung-Yu","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2025, June 16). WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240060241."},{"key":"ref_2","unstructured":"Centers for Disease Control and Prevention (CDC) (2025, June 16). Areas with Valley Fever, Available online: https:\/\/www.cdc.gov\/valley-fever\/areas\/index.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1196\/annals.1406.004","article-title":"Expanding Understanding of Epidemiology of Coccidioidomycosis in the Western Hemisphere","volume":"1111","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_4","unstructured":"Centers for Disease Control and Prevention (CDC) (2025, June 16). Reportable Fungal Diseases by State, Available online: https:\/\/www.cdc.gov\/fungal\/php\/case-reporting\/index.html."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Gorris, M.E., Ardon-Dryer, K., Campuzano, A., Casta\u00f1\u00f3n-Olivares, L.R., Gill, T.E., Greene, A., Hung, C.Y., Kaufeld, K.A., Lacy, M., and S\u00e1nchez-Paredes, E. (2023). Advocating for Coccidioidomycosis to Be a Reportable Disease Nationwide in the United States and Encouraging Disease Surveillance across North and South America. J. Fungi, 9.","DOI":"10.3390\/jof9010083"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Williams, S.L., and Chiller, T. (2022). Update on the Epidemiology, Diagnosis, and Treatment of Coccidioidomycosis. J. Fungi, 8.","DOI":"10.3390\/jof8070666"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3201\/eid3105.241338","article-title":"Recent and Forecasted Increases in Coccidioidomycosis Incidence Linked to Hydroclimatic Swings, California, USA","volume":"31","author":"Camponuri","year":"2025","journal-title":"Emerg. Infect. Dis."},{"key":"ref_8","unstructured":"CDC (2025, November 07). Reported Cases of Valley Fever, Available online: https:\/\/www.cdc.gov\/valley-fever\/php\/statistics\/index.html."},{"key":"ref_9","unstructured":"California Department of Public Health (2025, June 16). Substantial Rise in Coccidioidomycosis in California: Recommendations for California Healthcare Providers, Available online: https:\/\/www.cdph.ca.gov\/Programs\/OPA\/Pages\/CAHAN\/Substantial-Rise-in-Coccidioidomycosis-in-California-Recommendations-for-California-Healthcare-Providers.aspx."},{"key":"ref_10","unstructured":"U.S. Census Bureau (2025, November 07). 65 and Older Population Grows Rapidly as Baby Boomers Age, Available online: https:\/\/www.census.gov\/newsroom\/press-releases\/2020\/65-older-population-grows.html."},{"key":"ref_11","unstructured":"Szaniszlo, P.J., and Harris, J.L. (1985). Arthroconidium-Spherule-Endospore Transformation in Coccidioides immitis. Fungal Dimorphism: With Emphasis on Fungi Pathogenic for Humans, Springer."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/mmy\/myy123","article-title":"Coccidioidomycosis: What a long strange trip it\u2019s been","volume":"57","author":"Deresinski","year":"2019","journal-title":"Med. Mycol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Donovan, F.M., Shubitz, L., Powell, D., Orbach, M., Frelinger, J., and Galgiani, J.N. (2019). Early Events in Coccidioidomycosis. Clin. Microbiol. Rev., 33.","DOI":"10.1128\/CMR.00112-19"},{"key":"ref_14","unstructured":"Akram, S.M., and Koirala, J. (2023). Coccidioidomycosis, StatPearls Publishing."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3201\/eid1206.060028","article-title":"Coccidioidomycosis as a common cause of community-acquired pneumonia","volume":"12","author":"Valdivia","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1093\/cid\/ciw360","article-title":"2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis","volume":"63","author":"Galgiani","year":"2016","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_17","unstructured":"Centers for Disease Control and Prevention (CDC) (2025, June 16). Clinical Overview of Valley Fever, Available online: https:\/\/www.cdc.gov\/valley-fever\/hcp\/clinical-overview\/index.html."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkm424","article-title":"Early diagnosis of fungal infection in immunocompromised patients","volume":"61","author":"Barnes","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Freeman Weiss, Z., Leon, A., and Koo, S. (2021). The Evolving Landscape of Fungal Diagnostics, Current and Emerging Microbiological Approaches. J. Fungi, 7.","DOI":"10.3390\/jof7020127"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"a019299","DOI":"10.1101\/cshperspect.a019299","article-title":"Fungal diagnostics","volume":"4","author":"Kozel","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_21","unstructured":"Centers for Disease Control and Prevention (CDC) (2025, June 16). Testing Algorithm for Coccidioidomycosis, Available online: https:\/\/www.cdc.gov\/valley-fever\/hcp\/testing-algorithm\/index.html."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"ofx197","DOI":"10.1093\/ofid\/ofx197","article-title":"Top Questions in the Diagnosis and Treatment of Coccidioidomycosis","volume":"4","author":"Donovan","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_23","unstructured":"Valley Fever Center for Excellence (2025, June 16). Order the Right Tests. Available online: https:\/\/vfce.arizona.edu\/valley-fever-people\/order-right-tests."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1128\/JCM.02731-14","article-title":"Development of a Real-Time PCR Assay for Identification of Coccidioides immitis by Use of the BD Max System","volume":"53","author":"Mitchell","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Saubolle, M.A., Wojack, B.R., Wertheimer, A.M., Fuayagem, A.Z., Young, S., and Koeneman, B.A. (2018). Multicenter Clinical Validation of a Cartridge-Based Real-Time PCR System for Detection of Coccidioides spp. in Lower Respiratory Specimens. J. Clin. Microbiol., 56.","DOI":"10.1128\/JCM.01277-17"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1378\/chest.12-1312","article-title":"Coccidioidomycosis: Adenosine Deaminase Levels, Serologic Parameters, Culture Results, and Polymerase Chain Reaction Testing in Pleural Fluid","volume":"143","author":"Thompson","year":"2013","journal-title":"Chest"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1590\/S0036-46652015000700010","article-title":"The treatment of Coccidioidomycosis","volume":"57","author":"Ampel","year":"2015","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"ref_28","unstructured":"Valley Fever Center for Excellence (2025, June 16). Antifungal Therapy. Available online: https:\/\/health.ucdavis.edu\/valley-fever\/about-valley-fever\/treatment-antifungal-therapy\/index.html."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Thompson, G.R., Barker, B.M., and Wiederhold, N.P. (2017). Large-Scale Evaluation of In Vitro Amphotericin B, Triazole, and Echinocandin Activity against Coccidioides Species from U.S. Institutions. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.02634-16"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1439-0507.2006.01295.x","article-title":"A new, broad-spectrum azole antifungal: Posaconazole\u2013mechanisms of action and resistance, spectrum of activity","volume":"49","author":"Hof","year":"2006","journal-title":"Mycoses"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1301066","article-title":"Use of Oral Fluconazole during Pregnancy and the Risk of Birth Defects","volume":"369","author":"Pasternak","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"European Food Safety Authority (EFSA), European Centre for Disease Prevention and Control (ECDC), European Chemicals Agency (ECHA), European Environment Agency (EEA), European Medicines Agency (EMA), and European Commission\u2019s Joint Research Centre (JRC) (2025). Impact of the use of azole fungicides, other than as human medicines, on the development of azole-resistant Aspergillus spp.. EFSA J., 23.","DOI":"10.2903\/j.efsa.2025.9200"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kang, S.E., Sumabat, L.G., Melie, T., Mangum, B., Momany, M., and Brewer, M.T. (2022). Evidence for the agricultural origin of resistance to multiple antimicrobials in Aspergillus fumigatus, a fungal pathogen of humans. G3 (Bethesda), 12.","DOI":"10.1093\/g3journal\/jkab427"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wagner, R., Montoya, L., Head, J.R., Campo, S., Remais, J., and Taylor, J.W. (2023). Coccidioides undetected in soils from agricultural land and uncorrelated with time or the greater soil fungal community on undeveloped land. PLoS Pathog., 19.","DOI":"10.1371\/journal.ppat.1011391"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"i40","DOI":"10.1093\/jac\/dkaf002","article-title":"Coccidioidomycosis: A growing global concern","volume":"80","author":"Donovan","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"ofaa623","DOI":"10.1093\/ofid\/ofaa623","article-title":"Clinical and Economic Burden of Valley Fever in Arizona: An Incidence-Based Cost-of-Illness Analysis","volume":"8","author":"Grizzle","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wilson, L., Ting, J., Lin, H., Shah, R., MacLean, M., Peterson, M.W., Stockamp, N., Libke, R., and Brown, P. (2019). The Rise of Valley Fever: Prevalence and Cost Burden of Coccidioidomycosis Infection in California. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16071113"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Koutserimpas, C., Naoum, S., Raptis, K., Vrioni, G., Samonis, G., and Alpantaki, K. (2022). Skeletal Infections Caused by Coccidioides Species. Diagnostics, 12.","DOI":"10.3390\/diagnostics12030714"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-133-9-200011070-00009","article-title":"Comparison of Oral Fluconazole and Itraconazole for Progressive, Nonmeningeal Coccidioidomycosis","volume":"133","author":"Galgiani","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1128\/AAC.00332-06","article-title":"Comparison of Itraconazole and Fluconazole Treatments in a Murine Model of Coccidioidal Meningitis","volume":"51","author":"Kamberi","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"ofae010","DOI":"10.1093\/ofid\/ofae010","article-title":"MSG-15: Super-Bioavailability Itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses\u2014A Multicenter, Open-Label, Randomized Comparative Trial","volume":"11","author":"Spec","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1080\/17460913.2024.2362128","article-title":"SUBA-itraconazole in the treatment of systemic fungal infections","volume":"19","author":"Liu","year":"2024","journal-title":"Future Microbiol."},{"key":"ref_43","unstructured":"Food and Drug Administration (FDA) (2025, June 16). New Drug Application (NDA): 208901 (Tolsura\/Itraconazole), Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=208901."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1093\/ofid\/ofab466.120","article-title":"120. An open-label comparative trial of SUBA-itraconazole (SUBA) versus conventional itraconazole (c-itra) for treatment of proven and probable endemic mycoses (MSG-15): A pharmacokinetic (PK) and adverse Event (AE) analysis","volume":"8","author":"Pappas","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.2010.03680.x","article-title":"Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: An overview","volume":"70","author":"Lipp","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/cid\/cir642","article-title":"Treatment of Refractory Coccidioidomycosis with Voriconazole or Posaconazole","volume":"53","author":"Kim","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.07-0114","article-title":"Posaconazole Therapy for Chronic Refractory Coccidioidomycosis","volume":"132","author":"Stevens","year":"2007","journal-title":"Chest"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13693780802562969","article-title":"In vitro activities of isavuconazole against Opportunistic filamentous and Dimorphic fungi","volume":"47","year":"2009","journal-title":"Med. Mycol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lewis, J.S., Wiederhold, N.P., Hakki, M., and Thompson, G.R. (2022). New Perspectives on Antimicrobial Agents: Isavuconazole. Antimicrob. Agents Chemother., 66.","DOI":"10.1128\/aac.00177-22"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Heidari, A., Quinlan, M., Benjamin, D.J., Laurence, B., Mu, A., Ngai, T., Hoffman, W.J., Cohen, S.H., McHardy, I., and Johnson, R. (2019). Isavuconazole in the Treatment of Coccidioidal Meningitis. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.02232-18"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/cid\/ciad146","article-title":"Isavuconazole in the Treatment of Chronic Forms of Coccidioidomycosis","volume":"76","author":"Heidari","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses","volume":"63","author":"Thompson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","unstructured":"Food and Drug Administration (FDA) (2025, June 16). New Drug Application (NDA): 207500 (Cresemba\/Isavuconazonium Sulfate), Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=207500."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kovanda, L.L., Sass, G., Martinez, M., Clemons, K.V., Nazik, H., Kitt, T.M., Wiederhold, N., Hope, W.W., and Stevens, D.A. (2021). Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.02344-20"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/jac\/dkx410","article-title":"Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/mmy\/myz092","article-title":"The novel fungal CYP51 inhibitor VT-1598 displays classic dose-dependent antifungal activity in murine models of invasive aspergillosis","volume":"58","author":"Garvey","year":"2019","journal-title":"Med. Mycol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1093\/jac\/dky242","article-title":"The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis","volume":"73","author":"Garvey","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/jac\/dky170","article-title":"VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice","volume":"73","author":"Break","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wiederhold, N.P., Lockhart, S.R., Najvar, L.K., Berkow, E.L., Jaramillo, R., Olivo, M., Garvey, E.P., Yates, C.M., Schotzinger, R.J., and Catano, G. (2019). The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.02233-18"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"myae032","DOI":"10.1093\/mmy\/myae032","article-title":"Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: Phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598","volume":"62","author":"Gu","year":"2024","journal-title":"Med. Mycol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"624.e1","DOI":"10.1016\/j.ajog.2018.03.001","article-title":"A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis","volume":"218","author":"Brand","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"880.e1","DOI":"10.1016\/j.ajog.2022.07.023","article-title":"Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections","volume":"227","author":"Martens","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Nishimoto, A.T., Wiederhold, N.P., Flowers, S.A., Zhang, Q., Kelly, S.L., Morschh\u00e4user, J., Yates, C.M., Hoekstra, W.J., Schotzinger, R.J., and Garvey, E.P. (2019). In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00341-19"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Schell, W.A., Jones, A.M., Garvey, E.P., Hoekstra, W.J., Schotzinger, R.J., and Alexander, B.D. (2017). Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01817-16"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7815","DOI":"10.1128\/AAC.01437-15","article-title":"VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection","volume":"59","author":"Gebremariam","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/bjd.19224","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail","volume":"184","author":"Elewski","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Shubitz, L.F., Roy, M.E., Trinh, H.T., Hoekstra, W.J., Schotzinger, R.J., and Garvey, E.P. (2017). Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00111-17"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1128\/AAC.00593-15","article-title":"Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models","volume":"59","author":"Shubitz","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2217\/fmb-2021-0173","article-title":"Oteseconazole: An Advance in Treatment of Recurrent Vulvovaginal Candidiasis","volume":"16","author":"Sobel","year":"2021","journal-title":"Future Microbiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0079-6468(08)70148-6","article-title":"3 Biological Activity of Polyene Antibiotics","volume":"Volume 14","author":"Ellis","year":"1977","journal-title":"Progress in Medicinal Chemistry"},{"key":"ref_72","unstructured":"Abelcet (2025, June 16). Abelcet\u00ae (Amphotericin B Lipid Complex Injection). Available online: https:\/\/leadiant.com\/products\/abelcet\/."},{"key":"ref_73","unstructured":"AmBisome (2025, June 16). Turn to the Liposomal Amphotericin B Agent That Can Be Kinder to the Kidneys. Available online: https:\/\/www.ambisome.com\/."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1093\/cid\/ciz076","article-title":"Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B","volume":"68","author":"Groll","year":"2019","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_75","unstructured":"Noor, A., and Preuss, C.V. (2024). Amphotericin B, StatPearls Publishing."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11046-005-0177-0","article-title":"In vitro Activities of Caspofungin, Amphotericin B and Azoles Against Coccidioides posadasii Strains from Northeast, Brazil","volume":"161","author":"Cordeiro","year":"2006","journal-title":"Mycopathologia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.47.4.1376-1381.2003","article-title":"In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: Comparison of yeast-like and mycelial forms","volume":"47","author":"Nakai","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11046-007-9018-7","article-title":"Antifungal susceptibility profiles of Coccidioides immitis and Coccidioides posadasii from endemic and non-endemic areas","volume":"163","author":"Ramani","year":"2007","journal-title":"Mycopathologia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/jac\/dkm383","article-title":"Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model","volume":"60","author":"Gonzalez","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1128\/AAC.45.6.1854-1859.2001","article-title":"Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model","volume":"45","author":"Tijerina","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/cid\/cit113","article-title":"Treatment of pediatric refractory coccidioidomycosis with combination voriconazole and caspofungin: A retrospective case series","volume":"56","author":"Levy","year":"2013","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_83","first-page":"20499361231161387","article-title":"Flucytosine and its clinical usage","volume":"10","author":"Sigera","year":"2023","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Kelty, M.T., Miron-Ocampo, A., and Beattie, S.R. (2024). A series of pyrimidine-based antifungals with anti-mold activity disrupt ER function in Aspergillus fumigatus. Microbiol. Spectr., 12.","DOI":"10.1128\/spectrum.01045-24"},{"key":"ref_85","first-page":"143","article-title":"Stoffwechselprodukte von mikroorganismen. 154. Mitteilung. Nikkomycin, ein neuer hemmstoff der chitinsynthese bei pilzen","volume":"107","author":"Hagenmaier","year":"1976","journal-title":"Arch. Microbiol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Larwood, D.J. (2020). Nikkomycin Z\u2014Ready to Meet the Promise?. J. Fungi, 6.","DOI":"10.3390\/jof6040261"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1128\/jb.154.1.488-498.1983","article-title":"Inhibition of chitin synthesis in the cell wall of Coccidioides immitis by polyoxin D","volume":"154","author":"Hector","year":"1983","journal-title":"J. Bacteriol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Sass, G., Larwood, D.J., Martinez, M., Chatterjee, P., Xavier, M.O., and Stevens, D.A. (2021). Nikkomycin Z against Disseminated Coccidioidomycosis in a Murine Model of Sustained-Release Dosing. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.00285-21"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Wiederhold, N.P., Najvar, L.K., Jaramillo, R., Olivo, M., Larwood, D.J., and Patterson, T.F. (2024). Evaluation of nikkomycin Z with frequent oral administration in an experimental model of central nervous system coccidioidomycosis. Microbiol. Spectr., 12.","DOI":"10.1128\/spectrum.01356-24"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3109\/13693786.2013.770610","article-title":"Efficacy of Nikkomycin Z for respiratory coccidioidomycosis in naturally infected dogs","volume":"51","author":"Shubitz","year":"2013","journal-title":"Med. Mycol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/infdis\/jiu029","article-title":"Modeling nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials","volume":"209","author":"Shubitz","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Wiederhold, N.P. (2020). Review of the Novel Investigational Antifungal Olorofim. J. Fungi, 6.","DOI":"10.3390\/jof6030122"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Wiederhold, N.P., Najvar, L.K., Jaramillo, R., Olivo, M., Birch, M., Law, D., Rex, J.H., Catano, G., and Patterson, T.F. (2018). The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.00999-18"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Jallow, S., and Govender, N.P. (2021). Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor. J. Fungi, 7.","DOI":"10.3390\/jof7030163"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12281-021-00419-5","article-title":"Investigational Agents for the Treatment of Resistant Yeasts and Molds","volume":"15","author":"Seiler","year":"2021","journal-title":"Curr. Fungal. Infect. Rep."},{"key":"ref_98","first-page":"2061","article-title":"FDA Public Workshop Summary\u2014Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs","volume":"74","author":"Yasinskaya","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_99","unstructured":"Angulo, D. (2020, January 5). Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs. Proceedings of the Development Considerations for Coccidioidomycosis, Virtual."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1046\/j.1365-2958.2003.03481.x","article-title":"Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly","volume":"48","author":"Tsukahara","year":"2003","journal-title":"Mol. Microbiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis","volume":"56","author":"Watanabe","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Shaw, K.J., and Ibrahim, A.S. (2020). Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections. J. Fungi, 6.","DOI":"10.3390\/jof6040239"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Viriyakosol, S., Kapoor, M., Okamoto, S., Covel, J., Soltow, Q.A., Trzoss, M., Shaw, K.J., and Fierer, J. (2019). APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.01715-18"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Kim, J.H., Cheng, L.W., Chan, K.L., Tam, C.C., Mahoney, N., Friedman, M., Shilman, M.M., and Land, K.M. (2020). Antifungal Drug Repurposing. Antibiotics, 9.","DOI":"10.3390\/antibiotics9110812"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.drudis.2013.07.001","article-title":"Phenotypic screens as a renewed approach for drug discovery","volume":"18","author":"Zheng","year":"2013","journal-title":"Drug Discov. Today"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Saeger, S., West-Jeppson, K., Liao, Y.-R., Campuzano, A., Yu, J.-J., Lopez-Ribot, J., and Hung, C.-Y. (2025). Discovery of novel antifungal drugs via screening repurposing libraries against Coccidioides posadasii spherule initials. mBio, 16.","DOI":"10.1128\/mbio.00205-25"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Vazquez-Rodriguez, A., Yu, J.-J., Hung, C.-Y., and Lopez-Ribot, J.L. (2025). Development and Optimization of Multi-Well Colorimetric Assays for Growth of Coccidioides posadasii Spherules and Their Application in Large-Scale Screening. J. Fungi, 11.","DOI":"10.20944\/preprints202508.2128.v1"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"McMahon, C.L., Esqueda, M., Yu, J.-J., Wall, G., Romo, J.A., Vila, T., Chaturvedi, A., Lopez-Ribot, J.L., Wormley, F., and Hung, C.-Y. (2023). Development of an Imaging Flow Cytometry Method for Fungal Cytological Profiling and Its Potential Application in Antifungal Drug Development. J. Fungi, 9.","DOI":"10.3390\/jof9070722"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Mead, H.L., Valentine, M., Yin, H., III, G.R.T., Keim, P., Engelthaler, D.M., and Barker, B.M. (2024). In vitro small molecule screening to inform novel Candidates for use in fluconazole combination therapy in vivo against Coccidioides. Microbiol. Spectr., 12.","DOI":"10.1128\/spectrum.01008-24"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Biersack, B. (2024). The Antifungal Potential of Niclosamide and Structurally Related Salicylanilides. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115977"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4102\/jsava.v70i2.756","article-title":"The Pharmacology of Halogenated Salicylanilides and Their Anthelmintic Use in Animals","volume":"70","author":"Swan","year":"1999","journal-title":"J. S. Afr. Vet. Assoc."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Almeida-Paes, R., de Andrade, I.B., Ramos, M.L.M., Rodrigues, M.V.A., do Nascimento, V.A., Bernardes-Engemann, A.R., and Frases, S. (2021). Medicines for Malaria Venture COVID Box: A source for repurposing drugs with antifungal activity against human pathogenic fungi. Mem. Inst. Oswaldo Cruz, 116.","DOI":"10.1590\/0074-02760210207"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/1087057115594751","article-title":"Development and Application of a High-Throughput Screening Method to Evaluate Antifungal Activity against Trichophyton tonsurans","volume":"20","author":"Preuett","year":"2015","journal-title":"SLAS Discov."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"104187","DOI":"10.1016\/j.jddst.2023.104187","article-title":"The challenge of repurposing niclosamide: Considering pharmacokinetic parameters, routes of administration, and drug metabolism","volume":"81","author":"Jara","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_116","unstructured":"Hafiz, S., and Kyriakopoulos, C. (2024). Pentamidine. StatPearls, StatPearls Publishing LLC."},{"key":"ref_117","unstructured":"Food and Drug Administration (FDA) (2025, June 16). New Drug Application (NDA): 019887 (Nebupent\/Pentamidine Isethionate), Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"myac033","DOI":"10.1093\/mmy\/myac033","article-title":"Identification of four compounds from the Pharmakon library with antifungal activity against Candida auris and species of Cryptococcus","volume":"60","author":"Castelli","year":"2022","journal-title":"Med. Mycol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1128\/AAC.50.1.294-297.2006","article-title":"Pentamidine Is Active in a Neutropenic Murine Model of Acute Invasive Pulmonary Fusariosis","volume":"50","author":"Lionakis","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0304-3940(93)90709-T","article-title":"Pentamidine, an inhibitor of spinal flexor reflexes in rats, is a potent N-methyl-d-aspartate (NMDA) antagonist in vivo","volume":"155","author":"Block","year":"1993","journal-title":"Neurosci. Lett."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0922-4106(95)90107-8","article-title":"Inhibition of constitutive nitric oxide synthase in the brain by pentamidine, a calmodulin antagonist","volume":"289","author":"Yoshihisa","year":"1995","journal-title":"Eur. J. Pharmacol. Mol. Pharmacol."},{"key":"ref_122","unstructured":"National Center for Biotechnology Information (2025, June 16). PubChem Compound Summary for CID 50248, Triclabendazole, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Triclabendazole."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1439-0507.2012.02225.x","article-title":"The inhibitory effects of aureobasidin A on Candida planktonic and biofilm cells","volume":"56","author":"Tan","year":"2013","journal-title":"Mycoses"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bbrc.2023.04.099","article-title":"Activated EGFR and PDGFR internalize in separate vesicles and downstream AKT and ERK1\/2 signaling are differentially impacted by cholesterol depletion","volume":"665","author":"Olsson","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_126","first-page":"475","article-title":"SU014813 is a novel multireceptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity","volume":"65","author":"Grazzini","year":"2005","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/1087057113496847","article-title":"A High-Throughput Screening Assay for Fungicidal Compounds against Cryptococcus neoformans","volume":"19","author":"Rabjohns","year":"2014","journal-title":"SLAS Discov."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1200\/JCO.1998.16.1.348","article-title":"Tamoxifen and toremifene in breast cancer: Comparison of safety and efficacy","volume":"16","author":"Buzdar","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Ngan, N.T.T., Thanh Hoang Le, N., Vi Vi, N.N., Van, N.T.T., Mai, N.T.H., Van Anh, D., Trieu, P.H., Lan, N.P.H., Phu, N.H., and Chau, N.V.V. (2021). An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. eLife, 10.","DOI":"10.7554\/eLife.68929"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"eabq6089","DOI":"10.1126\/scitranslmed.abq6089","article-title":"Inhibition of p38\u03b1 MAPK restores neuronal p38\u03b3 MAPK and ameliorates synaptic degeneration in a mouse model of DLB\/PD","volume":"15","author":"Iba","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_132","unstructured":"Sidhu, G., and Preuss, C.V. (2024). Triamcinolone, StatPearls Publishing."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"9792","DOI":"10.1074\/jbc.M109.082305","article-title":"Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome","volume":"285","author":"Juliana","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives","volume":"11","author":"Chen","year":"2012","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_135","unstructured":"Sharma, A., and Preuss, C.V. (2023). Bortezomib, StatPearls Publishing."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Diep, A.L., and Hoyer, K.K. (2020). Host Response to Coccidioides Infection: Fungal Immunity. Front. Cell. Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.581101"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Singh, M., Kumar, S., Singh, B., Jain, P., Kumari, A., Pahuja, I., Chaturvedi, S., Prasad, D.V.R., Dwivedi, V.P., and Das, G. (2022). The 1,2-ethylenediamine SQ109 protects against tuberculosis by promoting M1 macrophage polarization through the p38 MAPK pathway. Commun. Biol., 5.","DOI":"10.1038\/s42003-022-03693-2"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jim.2008.02.016","article-title":"Development of a cell death-based method for the screening of nuclear factor-\u03baB inhibitors","volume":"335","author":"Chopra","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"21096","DOI":"10.1074\/jbc.272.34.21096","article-title":"Novel Inhibitors of Cytokine-induced I\u03baB\u03b1 Phosphorylation and Endothelial Cell Adhesion Molecule Expression Show Anti-inflammatory Effects in Vivo","volume":"272","author":"Pierce","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Watamoto, T., Egusa, H., Sawase, T., and Yatani, H. (2015). Screening of Pharmacologically Active Small Molecule Compounds Identifies Antifungal Agents Against Candida Biofilms. Front. Microbiol., 6.","DOI":"10.3389\/fmicb.2015.01453"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Ajetunmobi, O.H., Wall, G., Vidal Bonifacio, B., Martinez Delgado, L.A., Chaturvedi, A.K., Najvar, L.K., Wormley, F.L., Patterson, H.P., Wiederhold, N.P., and Patterson, T.F. (2023). High-Throughput Screening of the Repurposing Hub Library to Identify Drugs with Novel Inhibitory Activity against Candida albicans and Candida auris Biofilms. J. Fungi, 9.","DOI":"10.3390\/jof9090879"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00705-009-0471-0","article-title":"ST1859 reduces prion infectivity and increase survival in experimental scrapie","volume":"154","author":"Colombo","year":"2009","journal-title":"Arch. Virol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/21501203.2016.1204368","article-title":"Sertraline demonstrates fungicidal activity in vitro for Coccidioides immitis","volume":"7","author":"Paul","year":"2016","journal-title":"Mycology"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Breuer, M.R., Dasgupta, A., Vasselli, J.G., Lin, X., Shaw, B.D., and Sachs, M.S. (2022). The Antidepressant Sertraline Induces the Formation of Supersized Lipid Droplets in the Human Pathogen Cryptococcus neoformans. J. Fungi, 8.","DOI":"10.3390\/jof8060642"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1473-3099(19)30127-6","article-title":"Adjunctive sertraline for HIV-associated cryptococcal meningitis: A randomised, placebo-controlled, double-blind phase 3 trial","volume":"19","author":"Rhein","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_146","unstructured":"National Center for Biotechnology Information (2025, June 16). PubChem Compound Summary for CID 8567, Meglumine, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Meglumine."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11046-025-00948-4","article-title":"Synergistic Antifungal Activity of Pentamidine and Auranofin Against Multidrug-Resistant Candida auris","volume":"190","author":"Retore","year":"2025","journal-title":"Mycopathologia"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1080\/21505594.2016.1196301","article-title":"Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi","volume":"8","author":"Wiederhold","year":"2017","journal-title":"Virulence"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"de Abreu Almeida, M., Baeza, L.C., Silva, L.B.R., Bernardes-Engemann, A.R., Almeida-Silva, F., Coelho, R.A., de Andrade, I.B., Corr\u00eaa-Junior, D., Frases, S., and Zancop\u00e9-Oliveira, R.M. (2024). Auranofin is active against Histoplasma capsulatum and reduces the expression of virulence-related genes. PLoS Neglect. Trop. Dis., 18.","DOI":"10.1371\/journal.pntd.0012586"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4155\/fmc.15.182","article-title":"Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin","volume":"8","author":"Fuchs","year":"2016","journal-title":"Future Med. Chem."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Thangamani, S., Maland, M., Mohammad, H., Pascuzzi, P.E., Avramova, L., Koehler, C.M., Hazbun, T.R., and Seleem, M.N. (2017). Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets Mia40-Erv1 Pathway. Front. Cell. Infect. Microbiol., 7.","DOI":"10.3389\/fcimb.2017.00004"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"101381","DOI":"10.1016\/j.mycmed.2023.101381","article-title":"In vitro antifungal and antibiofilm activities of auranofin against itraconazole-resistant Aspergillus fumigatus","volume":"33","author":"Chen","year":"2023","journal-title":"J. Med. Mycol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1080\/21505594.2021.1909266","article-title":"Repurposing of auranofin and honokiol as antifungals against Scedosporium species and the related fungus Lomentospora prolificans","volume":"12","author":"Yaakoub","year":"2021","journal-title":"Virulence"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","article-title":"Auranofin: Repurposing an old drug for a golden new age","volume":"15","author":"Roder","year":"2015","journal-title":"Drugs R D"},{"key":"ref_155","unstructured":"National Center for Biotechnology Information (2025, June 16). PubChem Compound Summary for CID 4621, Oxethazaine, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Oxethazaine."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Jemel, S., Guillot, J., Kallel, K., Botterel, F., and Dannaoui, E. (2020). Galleria mellonella for the Evaluation of Antifungal Efficacy against Medically Important Fungi, a Narrative Review. Microorganisms, 8.","DOI":"10.3390\/microorganisms8030390"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Marena, G.D., Thomaz, L., Nosanchuk, J.D., and Taborda, C.P. (2025). Galleria mellonella as an Invertebrate Model for Studying Fungal Infections. J. Fungi, 11.","DOI":"10.3390\/jof11020157"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Mendoza Barker, M., Saeger, S., Campuzano, A., Yu, J.-J., and Hung, C.-Y. (2024). Galleria mellonella Model of Coccidioidomycosis for Drug Susceptibility Tests and Virulence Factor Identification. J. Fungi, 10.","DOI":"10.3390\/jof10020131"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Curtis, A., Binder, U., and Kavanagh, K. (2022). Galleria mellonella Larvae as a Model for Investigating Fungal\u2014Host Interactions. Front. Fungal Biol., 3.","DOI":"10.3389\/ffunb.2022.893494"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Smith, D.F.Q., Dragotakes, Q., Kulkarni, M., Hardwick, J.M., and Casadevall, A. (2022). Galleria mellonella immune melanization is fungicidal during infection. Commun. Biol., 5.","DOI":"10.1038\/s42003-022-04340-6"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Kavanagh, K., and Sheehan, G. (2018). The Use of Galleria mellonella Larvae to Identify Novel Antimicrobial Agents against Fungal Species of Medical Interest. J. Fungi, 4.","DOI":"10.3390\/jof4030113"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/mmy\/myy042","article-title":"Galleria mellonella as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment","volume":"57","author":"Maurer","year":"2018","journal-title":"Med. Mycol."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Vanhoffelen, E., Michiels, L., Brock, M., Lagrou, K., Res\u00e9ndiz-Sharpe, A., and Velde, G.V. (2023). Powerful and Real-Time Quantification of Antifungal Efficacy against Triazole-Resistant and -Susceptible Aspergillus fumigatus Infections in Galleria mellonella by Longitudinal Bioluminescence Imaging. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.00825-23"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Giammarino, A., Bellucci, N., and Angiolella, L. (2024). Galleria mellonella as a Model for the Study of Fungal Pathogens: Advantages and Disadvantages. Pathogens, 13.","DOI":"10.3390\/pathogens13030233"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1196\/annals.1406.029","article-title":"Experimental Animal Models of Coccidioidomycosis","volume":"1111","author":"Clemons","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1128\/iai.40.3.912-916.1983","article-title":"Inbred mouse strains differ in resistance to lethal Coccidioides immitis infection","volume":"40","author":"Kirkland","year":"1983","journal-title":"Infect. Immun."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/infdis\/jiaa419","article-title":"A Chronic Murine Disease Model of Coccidioidomycosis Using Coccidioides posadasii, Strain 1038","volume":"223","author":"Shubitz","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1128\/IAI.00459-09","article-title":"A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB\/c mice against coccidioidomycosis","volume":"77","author":"Xue","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1054\/drup.2000.0171","article-title":"The role of murine models in the development of antifungal therapy for systemic mycoses","volume":"3","author":"Graybill","year":"2000","journal-title":"Drug Resistance Updates"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/cpt.1846","article-title":"Does In Vitro Potency Predict Clinically Efficacious Concentrations?","volume":"108","author":"Hjorth","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"myad104","DOI":"10.1093\/mmy\/myad104","article-title":"Coccidioides species antifungal susceptibility testing: Experience from a large healthcare system in the endemic region","volume":"61","author":"Zangeneh","year":"2023","journal-title":"Med. Mycol."},{"key":"ref_173","unstructured":"Clinical and Laboratory Standards Institute (2008). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard, Clinical and Laboratory Standards Institute. [2nd ed.]. CLSI Document M38A2."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Miranda, N., and Hoyer, K.K. (2023). Coccidioidomycosis Granulomas Informed by Other Diseases: Advancements, Gaps, and Challenges. J. Fungi, 9.","DOI":"10.3390\/jof9060650"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1021\/acs.chemrev.7b00602","article-title":"Hit Generation in TB Drug Discovery: From Genome to Granuloma","volume":"118","author":"Yuan","year":"2018","journal-title":"Chem. Rev."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/11\/12\/875\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T05:17:47Z","timestamp":1765516667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/11\/12\/875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":175,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jof11120875"],"URL":"https:\/\/doi.org\/10.3390\/jof11120875","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]}}}